0001179110-19-010058.txt : 20190904 0001179110-19-010058.hdr.sgml : 20190904 20190904161911 ACCESSION NUMBER: 0001179110-19-010058 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20190903 FILED AS OF DATE: 20190904 DATE AS OF CHANGE: 20190904 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lutz Robert Matthew CENTRAL INDEX KEY: 0001786203 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37569 FILM NUMBER: 191074775 MAIL ADDRESS: STREET 1: 900 NORTHBROOK DRIVE STREET 2: SUITE 200 CITY: TREVOSE STATE: PA ZIP: 19053 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Strongbridge Biopharma plc CENTRAL INDEX KEY: 0001634432 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981130690 STATE OF INCORPORATION: L2 BUSINESS ADDRESS: STREET 1: 900 NORTHBROOK DRIVE, SUITE 200 CITY: TREVOSE STATE: PA ZIP: 19053 BUSINESS PHONE: (610) 254-9200 MAIL ADDRESS: STREET 1: 900 NORTHBROOK DRIVE, SUITE 200 CITY: TREVOSE STATE: PA ZIP: 19053 FORMER COMPANY: FORMER CONFORMED NAME: Cortendo AB DATE OF NAME CHANGE: 20150219 3 1 edgar.xml FORM 3 - X0206 3 2019-09-03 0 0001634432 Strongbridge Biopharma plc SBBP 0001786203 Lutz Robert Matthew 900 NORTHBROOK DRIVE SUITE 200 TREVOSE PA 19053 0 1 0 0 Chief Financial Officer Ordinary Shares 40811 D Stock Option (Right to Buy) 8.06 2015-10-06 2019-10-06 Common Stock 31818 D Stock Option (Right to Buy) 10.74 2016-10-06 2019-10-06 Common Stock 31818 D Stock Option (Right to Buy) 13.43 2017-10-06 2019-10-06 Common Stock 36363 D Stock Option (Right to Buy) 14.37 2025-06-25 Common Stock 7575 D Stock Option (Right to Buy) 14.37 2025-06-25 Common Stock 7575 D Stock Option (Right to Buy) 14.37 2025-06-25 Common Stock 7577 D Stock Option (Right to Buy) 3.94 2026-02-26 Common Stock 63000 D Stock Option (Right to Buy) 2.90 2027-02-23 Common Stock 175000 D Stock Option (Right to Buy) 6.65 2028-02-05 Common Stock 114000 D Stock Option (Right to Buy) 4.67 2029-02-20 Common Stock 110000 D Of the 40,811 shares, 24,500 ordinary shares are held in the form of restricted stock units, which vest in full on February 20, 2021, provided the Reporting Person is employed by the Issuer on such date. This option vested in 16 equal, quarterly installments beginning August 26, 2015, and is fully exercisable. This option vested in 16 equal, quarterly installments beginning October 16, 2015, and is fully exercisable. This option becomes 100% exercisable upon a change of control of the Issuer, provided the Reporting Person is employed by the Issuer on such date. This option vests in sixteen equal quarterly installments beginning May 26, 2016, provided the Reporting Person is employed by the Issuer on each vesting date. This option vests in sixteen equal quarterly installments beginning May 23, 2017, provided the Reporting Person is employed by the Issuer on each vesting date. This option vests in sixteen equal quarterly installments beginning May 5, 2018, provided the Reporting Person is employed by the Issuer on each vesting date. This option vests in sixteen equal quarterly installments beginning May 20, 2019, provided the Reporting Person is employed by the Issuer on each vesting date. Exhibit List: Exhibit 24 - Power of Attorney /s/ Stephen J. Long, as attorney-in-fact 2019-09-03 EX-24 2 ex24lutz20190828.txt POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS that the undersigned hereby constitutes, designates and appoints each of Stephen J. Long and Judith Goldberg as such person's true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution and full power to act alone and without the other, for the undersigned and in the undersigned's name, place and stead, in any and all capacities, to: (a) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID (or any successor form), including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) or any rule or regulation of the SEC promulgated thereunder; (b) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Strongbridge Biopharma plc (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder (or any successor forms); (c) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and (d) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact, except that in respect of any person herein appointed as an attorney-in-fact of the undersigned, this Power of Attorney shall be revoked and shall cease to be effective immediately with respect to such person at such time as such person shall no longer be employed by any of the Company and its subsidiaries. IN WITNESS WHEREOF, the undersigned has executed this instrument as of the 28th day of August, 2019. By:/s/ Robert Matthew Lutz ---------------------------- Name: Robert Matthew Lutz